KYKOF.US Kyowa Kirin Co. Ltd

Healthcare Pharmaceuticals USA Stocks
16.30 USD
Close of Nov 15, 2026
12.23 17.72
Market cap
USD 8.53B
P/E
16.1x
P/B
1.49x
ROE
7.6%
Dividend yield
2.69%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KYKOF.US undervalued?

Graham number
Price16.30
Graham value15.78
Premium3.3%

KYKOF.US trades 3.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kyowa Kirin Co. Ltd fundamental analysis

No fundamental analysis for Kyowa Kirin Co. Ltd yet.

Kyowa Kirin Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kyowa Kirin Co. Ltd

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for th…

Full company profile